The popularity of copyright’s blockbuster initially fueled a surge for pharma, nevertheless recent developments present a murky scenario for shareholders. Off-patent competitors are eating into profits, and ongoing patent challenges add further complexity to the situation. While specific companies may still gain from complementary products, the b